34265-55-9Relevant academic research and scientific papers
4-METHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALENES
-
Page/Page column 95-97, (2014/02/16)
The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
-
Paragraph 0565-0568; 0577, (2014/03/21)
The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
NOVEL SALTS OF (4-{[(5-{[(3-CHLOROPHENYL)METHYL]OXY}-2-METHYLPHENYL)CARBONYL]AMINO}-3-METHYLPHENYL)ACETIC ACID
-
Page/Page column 17-18, (2010/01/07)
A series of novel salt forms of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.
NOVEL POLYMORPHIC FORMS OF (4-{[(5-{[(3-CHLOROPHENYL)METHYL]OXY}-2-METHYLPHENYL)CARBONYL]AMINO}-3-METHYLPHENYL)ACETIC ACID
-
Page/Page column 18-19, (2010/01/07)
Polymorphic forms 1 and 2 of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2- methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid, pharmaceutical compositions comprising such polymorphs and the use of such polymorphs in medicine.
ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES
-
Page/Page column 34-35, (2009/05/29)
Disclosed is a compound of Formula (I) in which W and R1-R6 are defined herein. Also disclosed is a method of treating spinal muscular atrophy, as well as methods of using such compounds to increase SMN expression, increase EAAT2 expression, or increase the expression of a nucleic acid that encodes a translational stop codon introduced directly or indirectly by mutation or frameshift.
COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES
-
Page/Page column 17, (2009/12/27)
Compounds of Formula (I) or (II) useful for the treatment of spinal muscular atrophy or other uses, as well as methods of using such compounds to increase SMN expression, increase EAAT2 expression, or increase the expression of a nucleic acid that encodes
BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS
-
Page/Page column 77-78, (2008/12/06)
A compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein, R1, R2, R3, R4, R5, m, n and X are as defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.
Synthesis of calicoferol E and astrogorgiadiol, two marine 9,10- secosteroids
Della Sala, Giorgio,Izzo, Irene,De Riccardis, Francesco,Sodano, Guido
, p. 4741 - 4744 (2007/10/03)
The synthesis of two marine 9,10-secosteroids, calicoferol E and astrogorgiadiol, has been achieved starting from vitamin D3. The conceived approach establishes a general convergent Strategy toward the synthesis of 9,10-secosteroids.
Pharmaceutically active fluoromethyltyrosine compounds
-
, (2008/06/13)
This invention relates to novel monofluoromethyl- and difluoromethyltyrosine compounds which are active as tyrosine hydroxylase inhibitors and are therefore useful in the treatment of conditions caused by high levels of catecholamines such as hypertension
